S Mansbach - Avanos Medical Insider
| AVNS Stock | USD 18.68 0.47 2.45% |
Insider
S Mansbach is Senior Vice President Interim General Counsel, Corporate Secretary of Avanos Medical since 2021.
| Tenure | 3 years |
| Phone | 844 428 2667 |
| Web | https://avanos.com |
Avanos Medical Management Efficiency
The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0177 %, meaning that it created $0.0177 on every $100 dollars invested by stockholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erik Mickelson | Paragon 28 | 42 | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Denice Torres | Glaukos Corp | 60 | |
| Sam Park | Sight Sciences | 63 | |
| Gregory Davault | Axogen Inc | 56 | |
| Paul Rodio | Establishment Labs Holdings | 58 | |
| Michael Hutchinson | LivaNova PLC | 53 | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| Meghan Scanlon | Paragon 28 | 48 | |
| Karen Prange | Nevro Corp | 56 | |
| MBA BS | Sight Sciences | N/A | |
| B Johnson | Paragon 28 | 68 | |
| Julie Dewey | Nevro Corp | 63 | |
| BA Chemistry | Orthofix Medical | 63 | |
| Richard Carter | Nevro Corp | 53 | |
| L Katz | Glaukos Corp | N/A | |
| Anne Nunes | Anika Therapeutics | 54 | |
| Rajbir Denhoy | Establishment Labs Holdings | 53 | |
| Matt Jarboe | Paragon 28 | N/A | |
| Mark Quick | Orthofix Medical | N/A | |
| Laverne Council | CONMED | 59 | |
Management Performance
| Return On Equity | 0.0177 | ||||
| Return On Asset | 0.0208 |
Avanos Medical Leadership Team
Elected by the shareholders, the Avanos Medical's board of directors comprises two types of representatives: Avanos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avanos. The board's role is to monitor Avanos Medical's management team and ensure that shareholders' interests are well served. Avanos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avanos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heidi Kunz, Independent Director | ||
| Lee Burnes, Clinical RD | ||
| John Cato, Vice Resources | ||
| Michael Greiner, Chief Financial Officer, Senior Vice President | ||
| S Mansbach, Senior Vice President Interim General Counsel, Corporate Secretary | ||
| Scott Galovan, Vice Development | ||
| William Haydon, Senior Vice President and General Manager, Pain Management | ||
| Moji James, Senior Vice President General Counsel | ||
| Patrick OLeary, Independent Director | ||
| Sudhakar Varshney, Senior Procurement | ||
| Sigfrido Delgado, Senior Chain | ||
| John Byrnes, Independent Director | ||
| Julie Shimer, Independent Director | ||
| Michelle Scharfenberg, Senior Vice President Chief Ethics and Compliance Officer | ||
| Maria Sainz, Independent Director | ||
| Gary Blackford, Independent Non-Executive Chairman of the Board | ||
| William Hawkins, Independent Director | ||
| David Crawford, VP Treasurer | ||
| Arjun Sarker, Senior Vice President - International | ||
| David Ball, Senior Vice President - Global Supply Chain and Procurement | ||
| John Hurley, Principal Controller | ||
| Kerr Holbrook, Senior Vice President General Manager - Chronic Care | ||
| Joseph Woody, Chief Executive Officer, Director | ||
| Mojirade James, Senior Vice President General Counsel, Corporate Secretary |
Avanos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avanos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0177 | ||||
| Return On Asset | 0.0208 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 45.96 M | ||||
| Shares Owned By Insiders | 2.94 % | ||||
| Shares Owned By Institutions | 94.04 % | ||||
| Number Of Shares Shorted | 607.19 K | ||||
| Price To Earning | 51.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.